Overview
The investigators propose to initiate a study assessing the efficacy and safety of a lower initial dosage of lenvatinib combined with toripalimab in patients suffering from platinum-resistant recurrent ovarian cancer. The objective of this research is to offer a novel therapeutic approach for patients battling relapsed ovarian cancer with platinum resistance.
Eligibility
Inclusion Criteria:
- Age: 18 to 75 years;
- Platinum-resistant recurrence of epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
- According to the RECIST 1.1 criteria, there should be at least one measurable lesion or a CA 125 level of ≥ 70 IU/L.
- ECOG 0-2;
- Liver and Kidney Function: Serum creatinine levels should be ≤ 1.5 times the upper limit of the normal range.AST and ALT levels should be ≤ 2.5 times the upper limit of normal, or ≤ 5 times the upper limit of normal if liver metastases are present;total bilirubin should be ≤ 1.5 times the upper limit of the normal range.
- Participants of reproductive age must consent to the use of effective contraceptive methods throughout the duration of the study.Women of reproductive age must yield a negative result in serum or urine pregnancy tests.Non-lactating patients.
- Those who are expected to survive longer than 3 months. Patients were unconscious and volunteered to participate in the study.
Exclusion Criteria:
- Uncontrollable malignant hypertension;
- Imaging showed that the tumor invaded important blood vessels;
- Contraindications to the use of antiangiogenic agents;
- Contraindications to checkpoint inhibitors;
- Patients presenting with abdominal fistula, gastrointestinal perforation, and pelvic-abdominal abscess;
- Simultaneous involvement or engagement in another clinical trial within a one-month period that could potentially influence the outcomes of this study.
- Known hypersensitivity to study-related drugs or their excipients;
- Individuals with severe heart, liver, kidney, and other serious concurrent diseases that may pose a threat to life;
- Patients judged by the investigator to be inappropriate for participation in the study.